Clinical and genomic influence of sulindac on rectal mucosa in familial adenomatous polyposis

Diseases of the Colon and Rectum

Volumn 40, Issue 10, 1997, Pages 1156-1169

  Winde, Guenther ^a,e   Schmid, Kurt W ^b   Brandt, Burkhardt ^a   Müller, Oliver ^c   Osswald, Hans ^d  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c MAX PLANCK INSTITUTE OF MOLECULAR PHYSIOLOGY   (Germany)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^e UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Adenoma reversion; Familial adenomatous polyposis; Nonsteroidal anti inflammatory drugs

Indexed keywords

SULINDAC;

ADENOMATOUS POLYP; ADULT; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; COLON RESECTION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; MALE; ONCOGENE RAS; TREATMENT OUTCOME;

ADENOMATOUS POLYPOSIS COLI; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELL DIVISION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTESTINAL MUCOSA; KI-67 ANTIGEN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS P21(RAS); RECTUM; SULINDAC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030816407     PISSN: 00123706     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02055161     Document Type: Article

References (58)

1. Jagelman DG: Extracolonic manifestation of familial polyposis coli. Cancer Genet Cytogenet 1987;27:319-25.
2. Dozois RR: Restorative proctocolectomy and ileal reservoir. Mayo Clin Proc 1986;61:283-6.
3. Jagelman DG: Report from the 4th biennial meeting of the Leeds Castle Polyposis Group. Int J Colorectal Dis 1991;6:224-36.
4. Nugent KP, Phillips RK: Rectal cancer risk in older patients with familial adenomatous polyposis and an ileorectal anastomosis: a cause of concern. Br J Surg 1992;79;1204-6.
5. DeCosse JJ, Billow S, Neale K, et al.: Rectal cancer risk in patients treated for familial adenomtous polyposis. Br J Surg 1992;79:1372-5.
6. Nugent KP, Spigelman AD, Nicholls RJ, Talbot IC, Neale K, Phillips RK: Pouch adenomas in patients with familial adenomatous polyposis. Br J Surg 1993;80:1620.
7. Puthu D, Rajan N, Rao R, Rao L, Venugopal P: Carci-norm of the rectal pouch following restorative proctocolectomy: report of a case. Dis Colon Rectum 1992;35:257-60.
8. Hoehner JC, Metcalf AM: Development of invasive adenocarcinoma following celectomy with ileoanal anastomosis for familial polyposis coli: report of a case. Dis Colon Rectum 1994;37:824-8.
9. Bassuni MM, Billings PJ: Carcinoma in an ileanal pouch after restorative proctocolectomy for familial adenomatous polyposis. Br J Surg 1996;83:506.
10. Ziv Y, Church JM, Oakley JR, McGannon E, Fazio VW: Surgery for the teenager with familial adenomatous polyposis: ileo-rectal anastomosis or restorative proctocolectomy? Int J Colorectal Dis 1995;10:6-9.
11. Charneau J, D'Aubigny N, Burtin P, Person B, Boyer J: Micropolypes rectaux après colectomie totale pour polypose familiale: efficacite du sulindac. Gastroenterol Clin Biol 1990;14:153-7.
12. Friend WG: Sulindac suppression of colorectal polyps in Gardner's Syndrome. Am Fam Physician 1990;41:891-4.
13. Gonzaga RA, Lima FR, Carneiro S, Maciel J, Junior MA: Sulindac treatment for familial polyposis coli. Lancet 1985;1:751.
14. Iwama T, Imajo M, Mishima Y: Is sulindac effective for familial adenomatous polyposis. Int J Colorectal Dis 1991:6;235.
15. Labayle D, Fischer D, Vielh P, et al. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 1991;101:635-9.
16. Waddell WR, Ganser GF, Cerise EJ, Loughry RW: Sulindac for polyposis of the colon. Am J Surg 1989;157:175-9.
17. Waddell WR, Loughry RW: Sulindac for polyposis of the colon. J Surg Oncol 1983;24:83-7.
18. Giardiello FM, Hamilton SR, Krush AJ, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993;328:1313-6.
19. Rigau J, Pique JM, Rubio JM, Planas R, Tarrech JM, Bordas JM. Effects of long-term sulindac therapy on colonic polyposis. Ann Intern Med 1991;115:952-4.
20. Spagnesi MT, Tonelli F, Dolara P, Caderni G, Valanzano R, Anastasi A, Bianchini F. Rectal proliferation and polyp occurrence in patients with familial adenomatous polyposis after sulindac treatment. Gastroenterology 1994;106:362-6.
21. Nugent KP, Farmer KC, Spigelman AD, Williams CB, Phillips RK: Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with adenomatous polyposis. Br J Surg 1993;80:1618-9.
22. Muller A, Hurlimann R, Meyenberger C, Staub P, Kobler E, Ammann R: Sulindac in familial adenomatous polyposis coli-preliminary findings of a prospective study. Schweiz Med Wochenschr 1994;124:651-4.
23. Giardiello FM, Offerhaus JA, Tersmette AC, et al. Sulindac induced regression of colorectal adenomas in familial adenomtaous polyposis: evaluation of predictive factors. Gut 1996;38:578-81.
24. Winde G, Schmid KW, Schlegel W, Fischer R, Osswald H, Bunte H: Complete reversion and prevention of rectal adenomas in colectomized patients with familial adenomatous polyposis by rectal low-dose sulindac maintenance treatment. Dis Colon Rectum 1995;38:813-30.
25. Piazza GA, Rahm AL, Krutzsch M, et al. Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res 1995;55:3110-6.
26. Sinicrope FA, Ruan SB, Cleary KR, Stephens LC, Lee JJ, Levin B: bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res 1995;55:237-41.
27. Bankfalvi A, Navabi H, Bier B, Böcker W, Jasani B, Schmid KW: Wet autoclave pretreatment for antigen retrieval in diagnostic immunochemistry. J Pathol 1994;174:223-8.
28. Jass JR, Sobin LH: Histological typing of intestinal tumours. Berlin: Springer-Verlag, 1989:29-32.
29. Luke FJ, Schlegel W: A time-resolved fluoroimmunoassay for the determination of prostaglandin F2a. Clin Chim Acta 1990;189:257-66.
30. Motulsky H, ed. Intuitive biostatistics. New York: Oxford University Press, 1995.
31. Spagnesi MT, Tonelli F, Dolara P, et al. Rectal proliferation and polyp occurrence in patients with familial adenomatous polyposis after sulindac treatment. Gastroenterology 1994;106:362-6.
32. Winde G, Kautz G, Schmid KW, Osswald H, Bunte H: Magnesium oxide and α-tocopherol in treat ment of upper GI-tract adenomas in familial adenomatous polyposis. Int J Colorectal Dis 1996;11:104A.
33. Belchetz LA, Berk T, Bapat BV, Cohen Z, Gallinger S: Changing causes of mortality in patients with familial adenomatous polyposis. Dis Colon Rectum 1996;39:384-7.
34. Kashiwagi H, Spigelman AD, Talbot IC, Phillips RK: Overexpression of p53 in duodenal tumours in patients with familial adenomatous polyposis. Br J Surg 1996;83:225-8.
35. Fearon E, Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 1990;61:759-67.
36. Piazza. GA, Kulchak Rahm AL, Krutzsch M, et al. Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res 1995;55:3110-6.
37. Yamashita N, Minamoto T, Ochiai A, Onda M, Esumi H: Frequent and characteristic K-ras activation in aberrant crypt foci of colon. Cancer 1995;75:1527-33.
38. Minamoto T, Yamashita N, Ochiai A, et al. Mutant K-ras in apparantly normal mucosa of colorectal cancer patients. Cancer 1995;75:1520-6.
39. Singh J, Kelloff G, Reddy BS. Intermediate biomarkers of colon cancer: modulation of expression of ras oncogene by chemopreventive agents during azoxymethane-induced colon carcinogenesis. Carcinogenesis 1993;14:699-704.
40. Carney WP, Petit D, Hamer P, et al. Monoclonal antibody specific for an activated ras protein. Proc Natl Acad Sci 1986;83:7485-9.
41. Pullano TG, Sinn E, Carney WP. Characterizationof monoclonal antibody R256, specific for activated ras p21 with arginine at 12, and analysis of breast carcinoma of Harvey-ras transgenic mouse. Oncogene 1989;4:1003-8.
42. Hamer PJ, La Vecchio J, Ng SC, DeLellis R, Wolfe H, Carney WP: Activated Val-12 ras p21 in cell culture fluids and mouse plasma. Oncogene 1991;6:1609-15.
43. La Vecchio JA, Hamer PJ, Ng SC, Trimpe KL, Carney WP. Characterization of monoclonal antibodies specific to the activated rasp21 with aspartatic acid at position 13. Oncogene 1990;5:1173-8.
44. Singh J, Rao CV, Kulkarni N, Simi B, Reddy BS. Molecular markers as intermediate end-points in chemoprevention of colon cancer: modulation of ras activation by sulindac and phenylhexyliso-thiocyanate during colon carcinogenesis. Int J Oncol 1994;5:1009-18.
45. El-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-25.
46. Bagg A, Cossman J: BCL-2: physiology and role in neoplasia. In: Benz CC, Liu ET, eds. Oncogenes and tumor suppressor genes in human malignancies. Boston: Kluwer Academic Publishers, 1993:141-66.
47. Milner J, Metcalf EA: Cotranslation of activated mutant p53 with wild type drives the wild type p53 protein into the mutant conformation. Cell 1991;65:765-74.
48. Marks JR, Davidoff AM, Iglehart JD: p53 in human cancer. In: Garrett C, Sell S, eds. Cellular cancer markers. Totowa: Humana Press, 1995:77-110.
49. Howard SP, Park SJ, Hughes-Davies L, Coleman CN, Price BD: Suramin increases p53 protein levels but does not activate the p53 dependent G1 checkpoint. Clin Cancer Res 1996;2:269-76.
50. Shimamura A, Fisher DE: p53 in life and death. Clin Can Res 1996;2:435-40.
51. Sträter J, Koretz K, Günthert AR, Möller P: In situ detection of enterocytic apoptosis in normal colonic mucosa and in familial adenomatous polyposis. Gut 1995;37:819-25.
52. Lotem J, Sachs L: Regulation by bcl-2, c-myc, and p53 of susceptibility to induction of apoptosis by heat shock and cancer chemotherapy compounds in differentiation-competent and defective myeloid leukemic cells. Cell Growth Differ 1993;3:41-7.
53. Miyashita T, Krajewski S, Krajewska M, et al. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 1994;9:1799-805.
54. Hockenbery DM, Zutter M, Hickey W, Nahm M, Korsmeyer SJ: Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990;348:334-6.
55. Oltvai ZN, Milliman CL, Korsmeyer SJ: Bcl-2 heterodimers in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993;74:606-19.
56. Pasricha PJ, Bedi A, O'Connor K, et al. The effects of sulindac on colorectal proliferation and apop tosis in familial adenomatous polyposis. Gastroenterology 1995;109:994-8.
57. Joensuu H, Pylkkanen L, Toikkanen S: Bcl-2 protein expression and long-term survival in breast cancer. Am J Pathol 1994;145:1191-8.
58. Sinicrope FA, Ruan SB, Cleary KR, Stephens LC, Lee J Levin B: bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res 1995;55;237-41.